PENILAIAN KINERJA KEUANGAN PERUSAHAAN BUMN BIDANG FARMASI YANG TERDAFTAR DI BURSA EFEK INDONESIA PERIODE 2015-2018

Abstract

Abstrak: Penilaian Kinerja Keuangan Perusahaan BUMN Bidang Farmasi yang Terdaftar di Bursa Efek Indonesia Periode 2015-2018. Penelitian ini bertujuan untuk mengetahui kinerja keuangan perusahaan BUMN bidang farmasi yang terdaftar di Bursa Efek Indonesia periode 2015-2018 ditinjau dari hasil perhitungan Return On Equity (ROE), Return On Investment (ROI), Cash Ratio, Current Ratio, Collection Periods, Perputaran Persediaan, Total Assetss Turn Over (TATO), dan Rasio Total Modal Sendiri terhadap Total Aktiva serta perkembangan kinerja keuangan berdasarkan Keputusan Menteri BUMN Nomor: KEP-100/MBU/2002. Penelitian ini merupakan penelitian deskriptif kuantitatif. Subjek penelitian ini adalah PT Indofarma (Persero) Tbk dan PT Kimia Farma (Persero) Tbk, sedangkan objek penelitian ini adalah laporan keuangan tahunan PT Indofarma (Persero) Tbk dan PT Kimia Farma (Persero) Tbk periode 2015-2018. Teknik pengumpulan data yang digunakan adalah dokumentasi. Teknik analisis data menggunakan teknik evaluasi berdasarkan Surat Keputusan Menteri BUMN Nomor: KEP-100/MBU/2002. Adapun untuk menganalisis perkembangan kinerja keuangan menggunakan teknik analisis trend. Hasil penelitian menunjukkan bahwa: (1) Penilaian kinerja keuangan perusahaan BUMN bidang farmasi yang terdaftar di Bursa Efek Indonesia periode 2015-2018, dengan rincian (a) kinerja keuangan PT Indofarma (Persero) Tbk periode 2015 mendapatkan predikat Sehat kategori AAA, sedangkan periode 2016-2018 mendapatkan predikat Sehat kategori AA; (b) kinerja keuangan PT Kimia Farma (Persero) Tbk periode 2015-2018 mendapatkan predikat Sehat kategori AAA. (2) Perkembangan kinerja keuangan dari kedua perusahaan BUMN bidang farmasi periode 2015-2018 secara keseluruhan dengan bertumpu pada akumulasi bobot penilaian yang sudah diinterpolasikan menunjukkan trend kinerja yang cenderung mengalami penurunan.

Kata kunci: Evaluasi Kinerja Keuangan, BUMN Bidang Farmasi, Analisis Trend

Abstract: The Financial Performance Assessment Of State-Owned Pharmaceutical Enterprise Listed In Indonesia Stock Exchange During The Period From 2015-2018. This study aims to determine the financial performance of state-owned pharmaceutical companies listed on the Indonesia Stock Exchange for the period 2015-2018 in terms of the calculation of Return On Equity (ROE), Return On Investment (ROI), Cash Ratio, Current Ratio, Collection Periods, Inventory Turnover,Total Assetss Turn Over (TATO), and the Ratio of Total Own Capital to Total Assetss as well as the development of financial performance based on the Decree of the Minister of BUMN Number: KEP-100/MBU/2002. This research is quantitative descriptive. The subjects of this research are PT Indofarma (Persero) Tbk and PT Kimia Farma (Persero) Tbk, while the object of this research is the annual financial statements of PT Indofarma (Persero) Tbk and PT Kimia Farma (Persero) Tbk for the period 2015-2018. The data collection technique used is documentation. The data analysis technique used an evaluation technique based on the Decree of the Minister of SOEs Number: KEP-100/MBU/2002. As for analyzing the development of financial performance using trend analysis techniques. The results show that: (1) The financial performance assessment of state-owned pharmaceutical companies listed on the Indonesia Stock Exchange for the period 2015-2018, with details (a) the financial performance of PT Indofarma (Persero) Tbk in the 2015 period received the AAA category Healthy predicate, while the 2016 period -2018 received the title of Healthy category AA; (b) the financial performance of PT Kimia Farma (Persero) Tbk for the 2015-2018 period received a Healthy AAA category. (2) The overall development of the financial performance of the two state-owned companies in the pharmaceutical sector for the 2015-2018 period relying on the accumulated weight of the assessments that have been interpolated shows that the performance trend tends to decline.

Keywords: Financial Performance Evaluation, Pharmaceutical SOEs, Trend Analysis